VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Stage IV Rectal Cancer
Stage IV Colon Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer

Interventions: Drug: aflibercept

Registration Number: NCT00407654

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.

Detailed Description: PRIMARY OBJECTIVES:

I. Determine the response rate (complete and partial) in patients with previously treated metastatic colorectal cancer treated with VEGF Trap.

II. Determine the incidence of disease stabilization, in terms of 4-month progression-free survival, in patients treated with this drug.

SECONDARY OBJECTIVES:

I. Determine the median survival time of patients treated with this drug. II. Determine the 1-year survival rate and stable disease rate in patients treated with this drug.

III. Determine the response or stable disease duration in patients treated with this drug.

IV. Determine the toxicity of this drug in these patients. V. Determine the time to disease progression in patients treated with this drug.

VI. Determine if changes in free VEGF Trap levels correlate with response or toxicity.

OUTLINE: This is a multicenter, open-label study.

Patients are stratified according to prior bevacizumab treatment (yes vs no). Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at the beginning of each course and at 60 days after completion of study treatment. Samples are analyzed by immunoenzyme techniques to determine the pharmacokinetics of VEGF Trap.

After completion of study treatment, patients are followed at 30 and 60 days and then every 3 months thereafter.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 75

Inclusion Criteria

histologically/cytologically confirmed metastatic colorectal metastatic cancer
measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter) as>20mm with conventional techniques or as >10mm with spiral CT scan
>=4 weeks from major surgery
at least 1prior line of systemic therapy for metastatic disease. Prior treatment with anti-epidermal growth factor receptor inhibitors is allowed. Last dose >=4 weeks prior to randomization
Two cohorts: 1) bevacizumab naïveand; 2) bevacizumab treated
May have received prior thymidylate synthetase inhibitor concurrently with radiation as "radiation sensitizer". Last dose >=4 weeks prior to randomization
Prior radiation treatment >=4 weeks prior to randomization
Age>=18 years
Life expectancy >=3 months
ECOG<=2 (Karnofsky=60%)
leukocytes >3.0x10^9/L
absolute neutrophil count >1.5 x 10^9/L
platelets>75x10^9/L
INR <1.5 unless on warfarin
total bilirubin within 1.5xULN
AST/ALT≤2.5 X institution ULN
creatinine≤1.5xULN OR creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above1.5x institution limits
Urinalysis negative for protein OR 24h urine for protein <500 mg
full-dose anticoagulants with PT INR >1.5 eligible provided that: a) patient is therapeutic on stable dose of warfarin or low molecular weight heparin; b) patients on warfarin, the upper target for INR is <=3; c) no active bleeding/pathological condition carrying high bleeding risk
Eligibility of patients receiving medications known to affect activity/PK of VEGF Trap will be determined by PI
Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after completion of VEGF Trap therapy
Ability to understand/willingness to sign written informed consent

Exclusion Criteria

chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry
Other investigational agents concurrently
History of prior anti-angiogenic therapy other than bevacizumab
Evidence of CNS disease
Known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical/biologic composition to other agents used in the study.
Serious/non-healing wound/ulcer/bone fracture
History of abdominal fistula/GI perforation/bowel obstruction/intraabdominal abscess within 28 days of treatment
major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy
anticipation of need for major surgical procedures during study
core biopsy within 7 days prior to Day 1 therapy
Patients with clinically significant cardiovascular disease
Evidence of bleeding diathesis or coagulopathy
PT INR >1.5 unless the patient is on full-dose warfarin
Use of thrombolytic agents within 1 month of study initiation
Significant Proteinuria (>500mg/24h): Urine protein should be screened by random urinalysis for protein. If dipstick positive (>1+), 24-hour urine protein should be obtained and if >500mg/24 h, patient will be excluded.
Uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study
Pregnant women
HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for PK interactions with VEGF Trap

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm I	aflibercept	Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Progression-free Survival (Bevacizumab- naïve Group)	4 months	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group)
Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)	Up to 6 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
Progression-free Survival (Bevacizumab-treated Group)	4 months	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group)

Secondary Outcome Measures

Name	Time	Method
Objective Stable Disease Rate	Up to 6 years
Time to Progression	12 months	Kaplan-Meier method will be used.
Overall Survival (Bevacizumab-naïve Group)	12 months	Kaplan-Meier method will be used. (Bevacizumab- naïve Group)
Overall Survival (Prior Bevacizumab Treated Group)	12 months	Kaplan-Meier method will be used (Bevacizumab-naïve Group)
Number of Participants With Response (Bevacizumab-naïve Group)	Up to 6 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks
Overall Survival (Bevacizumab-treated Group)	12 months	Kaplan-Meier method will be used (Bevacizumab-treated Group)
Number of Participants With Response (Bevacizumab-treated Group)	Up to 6 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks